scout
|Videos|January 26, 2018

FDA Approval for Lutathera in Neuroendocrine Tumors

Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME